Extended Data Table 1 Summary of best overall response based on RECIST v.1.1 in participants with response according to CPS

From: Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial

  1. aThe 95% CI was based on the binomial exact CI method for ORR.
  2. bCalculation of DoR included participants with complete and partial responses.
  3. c,dFrom product-limit (Kaplan–Meier) method for censored data.
  4. CI, confidence interval; CPS, combined positive score; DoR, duration of response; NE, not estimable; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
Back to article page